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4Successful Expanded Program on Immunization (EPI) 
Initially Targeted Six Diseases
WHO/IVB database, 2017. Data as of 19 July 2017
World Health Organization 
(WHO) initiated Expanded 
Program on Immunization (EPI) 
in 1974 
● First six diseases targeted 
were diphtheria, pertussis, 
tetanus, measles, poliomyelitis, 
and tuberculosis
Substantial reduction in burden 
of childhood illness and deaths
5Global Causes of Death in Children Under Age 5 Years
www.who.int/mediacentre/factsheets/fs178/en/
An estimated 5.6 million 
deaths in children under 5 
years old each year
● 15,000 under-five deaths per day
15–25% are attributable to 
vaccine-preventable diseases
6Vaccines Available to Prevent 25 Infectious Diseases
WHO, 2012: Global Vaccine Action Plan 2011-2020
Significant advances 
made in development 
and introduction of 
new vaccines
Licensed vaccines 
available to prevent 25 
infectious diseases
7What is a “New” Vaccine?
Initial Vaccines
Universally Recommended 
Vaccines
Vaccines Recommended for 
Targeted Use
Diphtheria Haemophilus influenzae type B (Hib) Yellow fever
Pertussis Pneumococcal conjugate (PCV) Japanese encephalitis
Tetanus toxoid Rotavirus Typhoid conjugate
Measles Rubella Meningococcal
Oral poliovirus (OPV) Inactivated polio (IPV) Cholera
Bacille Calmette-Guerin (BCG) Human papillomavirus (HPV) Rabies
8Why We Need New Vaccines
1. Reduce child mortality from 
vaccine-preventable diseases
2. Prevent and control outbreaks of 
vaccine-preventable diseases
3. Eliminate and eradicate 
vaccine-preventable diseases
4. Respond to rapidly increasing 
antimicrobial resistance 
92011–2020: Decade of Vaccines and the 
Global Vaccine Action Plan (GVAP) Vision
WHO, 2012: Global Vaccine Action Plan 2011-2020
“We envision a world in which all 
individuals and communities enjoy 
lives free from vaccine-preventable 
diseases." 
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GVAP Mid-point Progress Targets 2015
DTP3: Third dose of Diphtheria Tetanus Pertussis vaccine  
WHO: 2017 SAGE Assessment Report of GVAP
1. DTP3: All countries >90% national coverage, 
and >80% in every district by end 2015
2. Polio: transmission stopped by end 2014
3. Maternal and neonatal tetanus: eliminated by 2015
4. Measles: eliminated in 4 regions by end-2015
5. Rubella: eliminated in 2 regions by end-2015
6. Introduction of new and under-utilized vaccines: 
At least 90 low- or middle-income countries to have 
introduced one or more such vaccines by 2015
ACHIEVED
NOT 
ACHIEVED
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New Vaccine Introduction GVAP Target Met
WHO: 2017 SAGE Assessment Report of GVAP
GVAP vaccine introduction 
target has been met 
and exceeded
Since 2010, 193 vaccines 
have been introduced 
in 108 of 138 low- and 
middle-income countries
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Progress in New Vaccine Introduction
Zipursky S, Patel M, Farrell M, et al. J Infect Dis. 2017 Jul 1;216(suppl_1):S15-S23.
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Countries with Haemophilus influenzae type b (Hib) Vaccine in 
National Immunization Program
WHO/IVB Database, as of 26 January 2018
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Incidence of Invasive Hib Disease Declines Following Hib Vaccine 
Introduction in Children Younger than 5 Years
Hib: Haemophilus influenzae type b
Hammitt LL, Crane RJ, Karani A, et al. Lancet Glob Health. 2016 Mar;4(3):e185-94
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Countries with Pneumococcal Conjugate Vaccine (PCV) in 
National Immunization Program
WHO/IVB Database, as of 26 January 2018
16
Reduction in Annual Pneumonia Incidence Following PCV 
Introduction in The Gambia
Mackenzie GA, Hill PC, Sahito, MS, et al. Lancet Infect Dis. 2017 Sep;17(9):965-973.
17
Countries with Rotavirus Vaccine in 
National Immunization Program
WHO/IVB Database, as of 26 January 2018
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Decrease in Rotavirus-positive Cases with Increasing Rotavirus 
Vaccine Coverage in Four African Countries, 2010–2015
Weldegebriel G, Mwenda JM, Chakauya J, et al. Vaccine. 2017 Oct 25. pii: S0264-410X(17)31458-5
19
Dramatic Reduction in Diarrheal Deaths Following Rotavirus 
Vaccine Introduction in Mexico
Richardson V, Parashar U, Patel M. N Engl J Med. 2011 Aug 25;365(8):772-3
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Countries with Human Papillomavirus (HPV) Vaccine 
in National Immunization Program
WHO/IVB Database, as of 26 January 2018
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Substantial Decline in Prevalence of HPV Types 6, 11, 16, 18 
Following HPV Vaccine Introduction
Markowitz LE, Hariri S, Lin C; et al. J Infect Dis. 2013 Aug 1;208(3):385-93  Oliver SE, Unger ER, Lewis R et al. J Infect Dis. 2017 Sep 1;216(5):594-603
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Efforts of Global Partners to Improve Vaccine Introduction in
Low- and Middle-income Countries
World Health Organization (WHO)
● Vaccine prequalification
● Global recommendations and policies
United Nations Children’s Fund (UNICEF)
● Communication and social mobilization
● Vaccine procurement
Gavi, the Vaccine Alliance (Gavi)
● Donor funding for eligible countries 
● Eligibility determined by country gross national income
● Vaccine market shaping through forecasting and assuring demand
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Estimated Impact of Vaccine Introduction in Gavi-eligible Countries
Lee LA, Franzel L, Atwell J, et al. Vaccine. 2013 Apr 18;31 Suppl 2:B61-72
By 2020, all or nearly all Gavi-eligible countries are projected to have 
introduced the following nine vaccines where recommended:
Hepatitis B Rotavirus Meningococcal serogroup A
Hib Rubella Japanese encephalitis
PCV Yellow fever Measles second dose
Estimated 23.3 million deaths will be averted by vaccines 
during 2011–2020, in 73 Gavi-eligible countries
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WHO Immunization Policy Framework and Decision-making 
on Vaccine Introduction
Adapted from:  World Health Organization and Strategic Advisory Group of Experts (SAGE) on Immunization
www.who.int/immunization/programmes_systems/policies_strategies/decision_making/en/
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Vaccine Supply Security and Procurement Can Hinder 
New Vaccine Introduction
Loharikar A, Dumolard L, Chu S. et al. MMWR 2016;65:1136–1140.
Recent supply shortages of rotavirus, PCV, IPV and HPV vaccines
● Vaccine markets and limited numbers of manufacturers
● Increasing demand and inaccurate supply forecasting
Countries may use programmatic modifications to address 
supply constraints
● Fractional doses of vaccines
● Phased introductions
Increasing vaccine manufacturing in middle-income countries can 
reduce price and increase supply
26
Global Mandates Can Facilitate Vaccine Introduction
polioeradication.org/wp-content/uploads/2016/07/PEESP_EN_A4.pdf
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Outbreaks of Vaccine-Preventable Diseases
Photo: © Unicef 
Require additional resources 
for vaccination campaigns
● Cholera outbreaks in Haiti, Zambia, and Yemen
● Yellow fever outbreaks in Angola and Brazil
May necessitate the use of vaccines 
before licensure
● Ebola in West Africa
Can occur during a humanitarian crisis
● Diphtheria among Rohingya refugees in Bangladesh
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Increasing Antimicrobial Resistance Necessitates 
Global Support for New Vaccine Introduction
Dagan R. Clin Microbiol Infect. 2009 Apr;15 Suppl 3:16-20
PCV introduction has prevented resistant infections and 
led to reduction in antibiotic use
Newer typhoid conjugate vaccine available
● Prequalified by WHO – January 2018
● Gavi-endorsed funding support for eligible countries
● Potential for high impact on prevention and control of antimicrobial-resistant 
typhoid fever
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Additional New and Pipeline* Vaccines across the Lifespan
*Vaccines shown in blue are in varying stages of development 
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Progress Made in New Vaccine Introduction but 
Need for Sustained Efforts
WHO, 2012: Global Vaccine Action Plan 2011-2020
Extensive progress in introducing new vaccines in low- and 
lower middle-income countries, meeting GVAP target
● Largely due to support from international partners and donors
● Significant reductions in vaccine-preventable disease and mortality 
Many factors affect the timing and prioritization of vaccine introduction
● Vaccine supply constraints and global mandates 
● Outbreaks and humanitarian crises  
● Increasing antimicrobial resistance 
Need for continued support of implementation to sustain health gains and 
work toward remaining GVAP targets
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Global Progress
Carsten Mantel, MD, MPH
Managing Director, MMGH Consulting GmbH, CH-Zürich
Senior Advisor Immunization, Department of Infectious Disease Epidemiology, 
Robert Koch Institute, D-Berlin
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Global Vaccine Action Plan (GVAP) Mission
WHO, 2012: Global Vaccine Action Plan 2011-2020
"The mission of the Decade of Vaccines is 
to extend, by 2020 and beyond, the full 
benefits of immunization to all people, 
regardless of where they are born, who 
they are, or where they live…”
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Vaccines and Equity—The Challenge Across Countries
www.who.int/gho/immunization/en/
Kirkwood CD, Steele AD. PLoS Med. 2017 May 9;14(5):e1002298.
 Inequity in new vaccine access across countries remains
We are still not reaching every child everywhere
● Nearly 1 in 10 infants worldwide has not received any DTP vaccine (12.9 million infants) 
● The global coverage of DTP3 is stagnating at around 86%
● Most of the unvaccinated and under-vaccinated children live in 10 large countries 
Rotavirus vaccine use is delayed in Asia
Middle-income countries are lagging in new vaccine introduction
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Numbers of Unvaccinated Children Falling 
in Some but Not All Large Countries
www.who.int/immunization/sage/meetings/2017/october/1_MacDonald_GVAP_SAGEOct2017.pdf
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Delay in Introducing Rotavirus Vaccine in Parts of Asia and Europe 
WHO/IVB Database, as of 26 January 2018
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Challenges for Middle-Income Countries (MICs)
www.worldbank.org/en/country/mic
www.who.int/immunization/programmes_systems/sustainability/WHO_MICTaskForce_StrategyLeaflet_P12_FINAL.pdf
● About two-thirds of the world’s poor now live in MICs
● For children, the largest fraction without access to new vaccines are born in MICs
● About one quarter of vaccine-preventable deaths occur in the MICs that are 
excluded from or are soon to lose donor support 
● 20 MICs are expected to transition from Gavi support by 2020
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Introduction of PCV Slower in Middle-Income Countries
www.who.int/immunization/sage/meetings/2017/october/1_MacDonald_GVAP_SAGEOct2017.pdf
Comparison of PCV Uptake in High-income, Gavi-eligible and Gavi-ineligible Countries, 2010–2016  
Gavi-eligible countries
Gavi-ineligible middle-
income countries
High-income countries
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Vaccines and Equity – The Challenge Within Countries
www.who.int/gho/immunization/en/ 
polioeradication.org/polio-today/preparing-for-a-polio-free-world/transition-planning/lessons-learned-from-polio-eradication/
 Inequity in vaccine delivery within countries is associated with:
● Conflicts, fragile situations, or humanitarian emergencies
● Residence (urban or rural), with low coverage in urban slums and remote 
rural communities
● Nomadic populations and ethnic minorities
● Economic status (wealth quintiles)
● Education (of mothers)
● Gender
● Vaccine hesitancy
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Increasing Proportion of Unimmunized Live in Cities 
and Urban Slums
Godwin Mindra, UNICEF.  Based on UN Population projections from www.unicef.org/health/files/Urban_profile_discussion_paper_vJune28.pdf
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Many Countries Show High Levels of Inequity
Differential in DTP3 coverage between highest and lowest wealth quintile
www.who.int/immunization/sage/meetings/2017/october/1_MacDonald_GVAP_SAGEOct2017.pdf
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Wealth quintile differential in percentage points
In certain countries, a child from a 
rich family is up to 9 times more 
likely to be vaccinated for DTP3 
than a child from a poor family.
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New Vaccines and Equity—The Response
GVAP: Global Vaccine Action Plan
Renewed global focus on equity across countries
● GVAP equity monitoring and response (WHO, UNICEF, World Bank)
● Gavi coverage and equity strategy  2016–2020
● Global Routine Immunization Strategies and Practices (GRISP)
● Middle-income country strategy 
 Increasing access to the unvaccinated within countries
● Governments often have difficulties in reaching these populations—or lack political will
● Community-based organizations play an important role in reaching the unimmunized and 
in increasing vaccine access and coverage—also related to new vaccines (e.g., IPV, HPV)
● New approaches to reach urban poor (slums), nomadic, marginalized populations
● New delivery and access strategies in crisis and humanitarian emergencies
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Gavi 2016–2020 Strategy Includes Equitable Uptake and Coverage
www.gavi.org/about/strategy/
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New Vaccines and Equity—The Response 
Middle-Income Country Strategy 2015–2020
www.who.int/immunization/programmes_systems/sustainability/WHO_MICTaskForce_StrategyLeaflet_P12_FINAL.pdf
Goal Enhance sustainable access to vaccines for populations in middle-income countries to meet GVAP targets
Objective Raise and sustain equitable immunization coverage and enable new vaccine introductions
Focus areas
①Strengthened 
decision making for 
timely and evidence-
based immunization 
policy and 
programmatic choices
② Increased political 
commitment and 
financial 
sustainability of 
immunization 
programs
③ Enhanced demand 
for and equitable 
delivery of 
immunization 
services
④ Improved access
to affordable and 
timely supply
Strategic 
enablers
Country commitment to and investment in immunization
Coordination among international and local partners
International and national advocacy & country-to-country peer learning
Strong monitoring & evaluation efforts
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New Vaccines and Hesitancy—The Response
www.euro.who.int/en/health-topics/communicable-diseases/measles-and-rubella/activities/tailoring-immunization-programmes-to-reach-
underserved-groups-the-tip-approach/the-tip-guide-and-related-publications
Efforts to address misperceptions 
and vaccine safety concerns
● Targeting and training health workers
● Identifying key influencers  
● Preparing Web and social media information
● Informing the public about decisions
Tailoring Immunization Programmes (TIP) tool 
● Toolkit for responding to vaccine-hesitant populations
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New Vaccine Products and Technologies 
Ensure Reach of Those Most in Need
cPAD: compact, pre-filled auto-disable injection device
Innovative vaccine products (thermostable, 
low multidose, monodose/prefilled, 
fractional dosing)
Innovative packaging (reduced volume)
Improved cold chain equipment
Innovative delivery technologies 
(intradermal devices, cPADs, microarray 
patches, electroporation, integrated 
reconstitution devices) 
Microarray Patch
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Improved Packaging and Presentation Reduces Stress on 
Supply Chains
VVM: Vaccine vial monitor                          www.who.int/immunization/programmes_systems/supply_chain/resources/tools/en/index4.html
Cold Chain volume per dose (cm3) varies by  secondary packaging: in one dose carton 115.3; in 10 dose carton 43.3; in 50 dose carton 17.1
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New Vaccine Delivery Technologies
Graphics ©:PATH Vaccine and Pharmaceutical Delivery Technologies; West Pharmaceutical Services; Georgia Tech; Uniject™; Rommelag;  
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Improving The Cold Chain
Pics: © Mantel C. 
49
New Vaccines: Strengthening Routine Immunization
GRISP: Global Routine Immunization Strategies and Practices at: www.who.int/immunization/programmes_systems/policies_strategies/GRISP/en/
www.apps.who.int/iris/bitstream/10665/204500/1/9789241510103_eng.pdf
 Increased focus on immunization, more 
advocacy and visibility
Opportunities for change in routine practices
Enhanced training
 Improved vaccine management (e.g., demand 
forecast, supply and logistics, cold chain)
 Improved data quality, collection, recording 
and reporting
Strengthened vaccine preventable disease surveillance 
 Improved adverse events reporting and management
Scannable vaccine record
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New vaccines: Delivering More to More 
Increasing Vaccine Access to More Populations Across The Life Course 
Photo: © Unicef 
New vaccines and life-course 
approach in immunization programs
● Birth dose
● EPI infant services 
● Second-year-of-life visit
● Pre-school vaccination
Regular joint child health visits 
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New Vaccines: Delivering More To More 
Deliver More New Vaccines In A More Integrated Way
Photo: © Unicef 
New vaccines delivered through non-immunization services 
and platforms 
● Antenatal services and maternal 
immunization (influenza, tetanus)
● School-based delivery (HPV)
● Adolescent health programs (HPV) 
● Services for the elderly (PCV, influenza)
● Disease-related services, 
e.g., diabetics and influenza
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Reducing Missed Opportunities for Vaccination
www.who.int/immunization/programmes_systems/policies_strategies/MOV/en/
A missed opportunity 
to vaccinate is…
any visit to a health service 
by a child (or adult) who is 
eligible for vaccination, 
that does not result in 
the person receiving
all the vaccine doses 
for which he or she is eligible
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Many Eligible Children Leave Health Facility 
Without Being Vaccinated
www.who.int/immunization/sage/meetings/2017/october/SAGE-Okwo_10.16.17.pdf
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In Chad, 15 Simple Strategies Reduced Missed Opportunities and 
Increased Vaccinations
www.who.int/immunization/sage/meetings/2017/october/SAGE-Okwo_10.16.17.pdf
Comparison of the Number of Vaccine Doses Given in Four 
Districts in Chad, May–August 2016, 2017   
One strategy was simply issuing 
vaccination coupons to cross-
refer children who visited for 
other reasons
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New Vaccines Linked with Other Health Interventions 
Will Take Us Further
Pics ©: Goodman T.
Other interventions delivered 
together with (new) vaccines
● Deworming (albendazole) 
● Vitamin A
● Long lasting impregnated nets
● Chemoprophylaxis
● Nutrition interventions 
● Water, sanitation, and hygiene
New collaborative approach 
to integration
Overburdened alone, or share the load together? 
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Financial and Economic Considerations 
Craig Burgess, MD, MSc, MBA
Senior Technical Advisor
JSI Training and Research Institute Inc. 
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High Return on Investment and Economic Benefits
Ozawa S, Clark S, Portnoy A, et al. Health Aff (Millwood). 2016 Feb;35(2):199-207
 For every $1 invested, 
immunizations pay back:
● $16 from costs associated  
with illness and lost productivity
● $44 from costs associated with  
broader economic impact of illness 
 New vaccines against pneumonia
(Hib, PCV) and diarrhea (rotavirus)
are significant contributions
to this investment
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Vaccines Are Cost-Effective and An Attractive Investment
Horton S, Gelband H, Jamison D, et al. PLoS One. 2017 Aug 10;12(8):e0182951
Vaccines are cost-effective
Most traditional and new vaccines cost less than:
● $100 per disability-adjusted life year averted (DALY)
● 3 times gross domestic product (GDP) per capita
Variability in cost effectiveness is due to context 
(e.g., disease burden in population, delivery mechanisms)
Vaccines are an attractive investment for essential health packages
● Vaccines are often more cost-effective than other basic health interventions
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New Vaccine Context: Understanding Complex Decision-Making
NITAG:  National Immunization Technical Advisory Group
Stakeholders
● Political, finance, civil society, 
and private
● NITAG, Interagency Coordinating 
Committee (ICC), Ministry of Health, 
Ministry of Finance
Decentralized decision-making
● Decisions on budget and 
planning to districts
Views on sustainability differ
● Economist and community views
60
New Vaccine Context of Decision-Making
Principles and considerations for adding a vaccine to a national immunization program From decision to implementation and monitoring
www.who.int/immunization/programmes_systems/policies_strategies/vaccine_intro_resources/nvi_guidelines/en/ 
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New Vaccine Context of Integration Into System
www.who.int/immunization/programmes_systems/policies_strategies/vaccine_intro_resources/nvi_guidelines/en/  
New vaccines need to fit into:
● Essential health packages
● Integrated delivery platforms
● Planning and budgeting
Evidence needed for decisions
● Economics, disease burden, delivery, cold chain
Decision-making about how, where, and when
Decisions need compromise and trade-offs
Communicating results and opportunities
● Raises awareness and demand, and reduces hesitancy
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Cost to Fully Immunize a Child Is Rising
and New Vaccine Prices Are Major Contributor
https://www.msfaccess.org/sites/default/files/VAX_The_Right_Shot_Report_2ndEd_2015.pdf 
Vaccine prices are main cost driver in immunization programs
● Price for all recommended vaccines increased by 68 times during 2001–2014
Most increases in cost are driven by the price of newer vaccines
Year Vaccine Prices Vaccines
2001 $0.67 6 initial antigens  (OPV, DTP, measles, BCG)
2014
$32.09 fully immunized boy 
(11 antigens) 
$45.59 fully immunized girl 
(11 antigens + HPV)
11 antigens in total
6 initial antigens  +  Hepatitis B,  PCV,  rubella,  rotavirus,  IPV, 
and Haemophilus influenzae type b (Hib)
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New Vaccine Delivery
Photo: © Unicef
Increasing cost per child immunized, as 
coverage increases (e.g., harder to reach)
Increasing use of campaigns to deliver in 
certain contexts
Investing in delivery systems is crucial if 
vaccines are to:
● Reach those with greatest disease 
burden (equity)
● Maximize cost-effectiveness
● Protect investment in new vaccines
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After Vaccines, The Main Cost Driver Is Systems Related
www.who.int/bulletin/volumes/92/5/13-130146/en/ 
Estimated Systems Costs (Service Delivery and Supply Chain) 
from Decade of Vaccines Work, 2011–2020
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New Vaccine Cost Considerations
Equity: link to health sector, primary health care, Reaching Every District 
or Community plans
Multiple shared costs: staff, transport, facilities
Effectiveness of delivery: timeliness, safety, and strategy (outreach, fixed 
post, school-based, workplace, campaigns, child health days)
Community participation:  sustainability, acceptability and uptake 
Tools, repository, and community of practice for costing and financing: 
www.immunizationeconomics.org and www.immunizationfinancing.org
Hosseinpoor AR, Bergen N, Schlotheuber A, et al. Lancet Glob Health. 2016 Sep;4(9):e617-26.
Chan Soeung S, Grundy J, Duncan R, et al. Health Policy Plan. 2013 Aug;28(5):526-35.
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New Vaccine Budgeting
data.worldbank.org/indicator/SH.XPD.PCAP 
Realistic budgets—
a political process that 
needs better evidence
‘On’ budget or ‘off’ budget?
What is affordable when:
● Expenditure on health is low?
● There are competing priorities?
● Delivery of routine vaccines 
is incomplete?
Country 
Classification
2014 Average 
Health 
Expenditure 
Per Capita (US$)
Number
of 
countries
Low income $37 31
Lower 
middle-income
$92 54
Middle income $290 103
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Transitioning from Gavi and Global Polio Eradication Initiative 
(GPEI) Support
Transition plans require dialogue with broad health systems planners
Address country management of logistics and supply need
Plan and budget for future new vaccines
Focus on domestic resource mobilization
Sustainability and capacity of institutions 
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New Vaccine Financing – What to Ask Before Starting  
www.immunizationfinancing.org
Key questions for countries to ask 
● Is the financing really additional?  
● Is there a ‘hidden’ cost to new financing? 
● Is the funding predictable and sustainable? 
● How flexible is the financing? 
● Will funding flow equitably?
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New Vaccine Financing – Finding the Funding
PAHO: Pan American Health Organization
www.immunizationfinancing.org
Domestic resources for funding
● Tax (“sin”/earmark), risk pooling, user fees, national trust funds, loans, budget 
support, universal health care advocacy for health budget 5% GDP
Reducing costs of vaccines through pooled procurement for vaccines
● Gavi, Vaccine Independence Initiative (VII), accessing UNICEF prices, and 
PAHO Revolving Fund 
Increasing efficiency to lower spending
● Decrease vaccine wastage and drop out, integration, increase social mobilization
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Strengthening New Vaccine Introduction
National decision-making requires increasing awareness and 
use of evidence (disease burden, economics, systems) and 
understanding politics
Translating global policy making to national action requires 
context-specific approaches and an understanding of stakeholders
New vaccine introduction has a role to play in economic development as 
well as disease control with very positive return on investment  
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New Vaccine Implementation: The Way Forward
Improve integration of service delivery at all levels
● Optimize vaccination schedules and broaden life-course approach
● Reduce missed opportunities for vaccination
● Use opportunities for ‘collaborative’ integration of immunization with other 
programs and sectors 
Reduce inequity in immunization across and within countries
● Implement GVAP, Reaching Every District or Community (focus on hard to reach)
● Strengthen country immunization delivery systems and reduce vaccine hesitancy
● Improve presentation and packaging and new delivery technologies
Reinforce alignment between immunization, global health, and 
development agendas 
● e.g., sustainable development goals and universal health coverage
